Literature DB >> 17125279

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Daniele Fancelli1, Jürgen Moll, Mario Varasi, Rodrigo Bravo, Roberta Artico, Daniela Berta, Simona Bindi, Alexander Cameron, Ilaria Candiani, Paolo Cappella, Patrizia Carpinelli, Walter Croci, Barbara Forte, Maria Laura Giorgini, Jan Klapwijk, Aurelio Marsiglio, Enrico Pesenti, Maurizio Rocchetti, Fulvia Roletto, Dino Severino, Chiara Soncini, Paola Storici, Roberto Tonani, Paola Zugnoni, Paola Vianello.   

Abstract

The optimization of a series of 5-phenylacetyl 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives toward the inhibition of Aurora kinases led to the identification of compound 9d. This is a potent inhibitor of Aurora kinases that also shows low nanomolar potency against additional anticancer kinase targets. Based on its high antiproliferative activity on different cancer cell lines, favorable chemico-physical and pharmacokinetic properties, and high efficacy in in vivo tumor models, compound 9d was ultimately selected for further development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17125279     DOI: 10.1021/jm060897w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  47 in total

1.  The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.

Authors:  Eduard R Felder; Alessandra Badari; Teresa Disingrini; Sergio Mantegani; Christian Orrenius; Nilla Avanzi; Antonella Isacchi; Barbara Salom
Journal:  Mol Divers       Date:  2012-02-15       Impact factor: 2.943

Review 2.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

Review 3.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 4.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 5.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

6.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

7.  The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors:  Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal:  J Comput Aided Mol Des       Date:  2011-01-11       Impact factor: 3.686

8.  Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3.

Authors:  Martin Golkowski; Gayani K Perera; Venkata Narayana Vidadala; Kayode K Ojo; Wesley C Van Voorhis; Dustin J Maly; Shao-En Ong
Journal:  Mol Omics       Date:  2018-02-12

Review 9.  ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Authors:  Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli
Journal:  Target Oncol       Date:  2013-01-17       Impact factor: 4.493

Review 10.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.